Prevalence of autoimmune comorbidities in patients with metastatic melanoma in the US.

Qiufei Ma, Mark Shilkrut, Minming Li, Beth Barber, Zhongyun ZhaoJournal of Clinical Oncology 2016 · DOI

Abstract

9529 Background: Immunotherapies have advanced the treatment of metastatic melanoma (MM); however they are associated with frequent immune-related toxicities. As a result, patients with pre-existing autoimmune conditions were commonly excluded from clinical trials studying immunotherapies in metastatic melanoma. Since limited information is available on pre-existing autoimmune comorbidities in “real-world” patients with MM, we sought to estimate prevalence of autoimmune comorbidities and the change over time in this population. Methods: Definitions of autoimmune disorders included in this study were obtained from the American Autoimmune-Related Diseases Association. Prevalence of autoimmune disorders and time trend over a period of 10 years from 2004 to 2014 were estimated in patients with newly diagnosed mm as well as in patients with newly diagnosed non-MM, and in the general population. Prevalence rates and trends were compared among these 3 populations to delineate the potential role of disease vis-à-vis time on prevalence trends. Data were obtained from MarketScan, a large US claims database. Logistic regression analyses were performed to evaluate the relationship between risk factors and pre-existing autoimmune disorders in MM. Results: A list of 147 autoimmune disorders was examined in this study. Among 12,028 patients with newly-diagnosed MM, the prevalence rate for autoimmune disorders increased 1.7-fold from 17.1% in 2004 to 28.3% in 2014 (P < 0.001). The prevalence rates were lower in patients with non-MM (11.7% in 2004 to 19.8% in 2014) and in the general population (7.9% in 2004 to 9.2% in 2014), but the rates increased 1.7- and 1.2-fold over time, respectively. Additionally, female, bone or gastrointestinal metastasis, and high comorbid disease burden were found to be associated with higher risk of autoimmune disorders. Conclusions: Prevalence of autoimmune comorbidities is high and increases over time in patients with newly diagnosed metastatic melanoma. Comorbid autoimmune disorders should be taken into consideration when treatment decisions are made.
BibTeX
@article{ma2016prevalence,
  author = {Qiufei Ma and Mark Shilkrut and Minming Li and Beth Barber and Zhongyun Zhao},
  title = {{Prevalence of autoimmune comorbidities in patients with metastatic melanoma in the US.}},
  journal = {Journal of Clinical Oncology},
  year = {2016},
  doi = {10.1200/jco.2016.34.15\_suppl.9529},
}

Loading related content...

Figure